Librela for Canine Osteoarthritis: Pain Relief or Hidden Risks?
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Librela for Canine Osteoarthritis: Pain Relief or Hidden Risks?
-
ナレーター：
-
著者：
このコンテンツについて
In this episode of The Pet Longevity Lab Podcast, we take a closer look at Librela (bedinvetmab), the FDA-approved monoclonal antibody for canine osteoarthritis pain management. While Librela is marketed as a breakthrough in pain relief, recent reports—including an FDA Dear Veterinarian Letter—raise serious concerns about its safety, long-term effects, and potential risks of accelerated disease progression.
We explore the mechanism behind Librela’s NGF blockade, why blocking pain without addressing joint degeneration may lead to unnoticed microtrauma and worsening osteoarthritis, and the FDA-reported adverse events such as ataxia, seizures, paresis, and even euthanasia cases.
Plus, we discuss alternative approaches, including Testosterone Replacement Therapy (TRT) and Adequan (PSGAGs), which offer joint support, metabolic benefits, and regenerative potential rather than just masking symptoms.
Tune in as we break down the science, the risks, and the best approaches for keeping senior dogs active, healthy, and truly supported in their osteoarthritis care. Is Librela really the best solution, or are there better, safer alternatives? Listen in to find out!